Equity · Healthcare
BMRN
NASDAQBioMarin Pharmaceutical (BMRN)
The line runs 69 USD on 13 August through 57.12 USD on 10 November, on a scale from 50 to 70. Days the market did not trade hold the previous close, flat.
- Market cap
- 11.1B USD
- Revenue, year to Dec 2025
- 3.2B USD
- EPS, diluted, year to Dec 2025
- 1.80 USD
- 52-week range
- 49.67 USD – 70.23 USD
- Avg volume
- 160.3K
as of Nov 9, 2026
Have BioMarin Pharmaceutical (BMRN) insiders bought or sold shares recently?
In the 90 days to 11 Nov 2026, BioMarin Pharmaceutical insiders reported 1 open-market sale and no purchases (SEC Form 4); the filings we hold, back to 1 Dec 2025, show no open-market purchase.
Form 4, 90 days to 11 Nov 2026, newest reported trade 2 Sep 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 02 Sep 2026 | Davis George EricEVP, Chief Legal Officer | Sell | 17,557 | 1.2M USD |
2 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 30 Sep 2026 | Friberg Gregory REVP, Chief R&D Officer | Tax withheld | 4,086 | 245K USD |
| 10 Sep 2026 | Plenge Robert MDirector | Award | 6,140 |
Which funds hold BioMarin Pharmaceutical (BMRN)?
0 of the 45 institutional funds we track reported a BioMarin Pharmaceutical position for the quarter ended 30 Sep 2026; the latest of those filings landed 06 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Fisher Asset Management | Exited |
Have members of Congress traded BioMarin Pharmaceutical (BMRN)?
The most recent congressional trade disclosed in BioMarin Pharmaceutical is a sale by Daniel S. Goldman (house, NY), dated 06 Mar 2023.
STOCK Act disclosures
| Traded | Member | Type | Amount | Filed after |
|---|---|---|---|---|
| 06 Mar 2023 | Daniel S. Goldmanhouse · Democrat–NY | Sale | 1K USD–15K USD | 42 days |
| 25 Mar 2019 | David J. Taylorhouse · Republican–OH | Sale | 1K USD–15K USD | 21 days |
What has been filed or recorded for BioMarin Pharmaceutical (BMRN)?
The filings we hold for BioMarin Pharmaceutical, newest first: 3 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 09 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 09 Oct 2026 | Fails to deliver | Shares failed to deliver | 97 shares | 5K USD notional · <0.001% of shares out |
| 05 Oct 2026 | Fails to deliver | Shares failed to deliver | 38,871 shares | 2.2M USD notional · 0.020% of shares out |
| 30 Sep 2026 | Fails to deliver | Shares failed to deliver | 260 shares | 16K USD notional · <0.001% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −0.63 USD | |
| 30 Sep 2026 | Financials | Total assets | 11.6B USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 6.3B USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS 0.23 USD | |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS 0.54 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS 1.80 USD | |
| 31 Dec 2025 | Financials | Revenue | 3.2B USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | 348.9M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | 1.80 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.16 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS 1.23 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS 0.95 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS 2.21 USD |
What do people ask about BioMarin Pharmaceutical (BMRN)?
What did BioMarin Pharmaceutical shares close at?57.12
BioMarin Pharmaceutical closed at 57.12 USD on 10 Nov 2026, down 0.12% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is BioMarin Pharmaceutical’s market cap?11.1B
BioMarin Pharmaceutical is worth 11.1B USD by market value as of 9 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is BioMarin Pharmaceutical’s revenue?3.2B
BioMarin Pharmaceutical reported revenue of 3.2B USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have BioMarin Pharmaceutical insiders bought or sold shares recently?1 sale
In the 90 days to 11 Nov 2026, BioMarin Pharmaceutical insiders reported 1 open-market sale and no purchases (SEC Form 4); the filings we hold, back to 1 Dec 2025, show no open-market purchase. A further 2 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own BioMarin Pharmaceutical?0 of 45
0 of the 45 funds we track reported a BioMarin Pharmaceutical position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported position was Fisher Asset Management. See Funds
Have members of Congress traded BioMarin Pharmaceutical?2 trades
Yes. 2 trades in BioMarin Pharmaceutical appear in the congressional disclosures we hold; the latest is a sale by Daniel S. Goldman (House, NY) dated 6 Mar 2023, filed 17 Apr 2023. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress
When did BioMarin Pharmaceutical last report earnings?−0.63
BioMarin Pharmaceutical last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.63 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- Wikimedia CommonsPortraits via Wikimedia Commons. David J. Taylor: Ike Hayman, House Creative Services, Public domain; Daniel S. Goldman: US House, Public domain.
- House disclosuresU.S. House of Representatives financial disclosures
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings